Jing Wen

Jing Wen is an Assistant Adjunct Professor at the University of California, Los Angeles (UCLA), School of Medicine. Their research focuses on developing advanced biologics through nano-encapsulation and molecular architecture to address therapeutic limitations such as biodistribution, stability, and immunogenicity. Key areas include immunotherapy, gene therapy, and nanotechnology applications in viral infections, central nervous system diseases, and cancers. Wen leads or co-leads multiple NIH-funded projects, including improving bNAb delivery for CNS infections and antioxidant enzyme therapies for SARS-CoV-2. Their work spans preclinical models (e.g., HIV, SHIV, cancer metastasis) and involves collaborations in translational research.

• Education: B.S. Chemical Engineering (Dalian University of Technology, 2006), Ph.D. Biomedical Engineering (Tianjin University, 2011).
• Postdoctoral training at UCLA (2016) and Project Scientist role (2020) further specialized in immunotherapy and gene therapy.

Research emphasizes targeted drug delivery systems, with publications in Small, Science Translational Medicine, and Advanced Materials. Notable contributions include nanocapsule-mediated T-cell boosting in cancer immunotherapy and CNS delivery mechanisms for antibodies.

Grants include NIH R01NS137919 (2024-2029) as PI and NSF DBI-2345571 (2024-2027) as Co-PI. Their lab (Wen Lab) develops platforms for protein therapeutics and nanomedicine, addressing challenges in drug delivery to the CNS and tumors.